TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16051118

Group type: EXPERIMENTAL
Intervention: DDDR RV pacing > 40%
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: DDDR RV pacing <= 40%
Number of subjects: 380

Group type: COMPARATOR
Intervention: VVI group
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 380
Study: 12469002

Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 75 mg/day)
Number of subjects: 10
Study: 9855508

Group type: EXPERIMENTAL
Intervention: Pergolide (0.05 to 0.65 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8308518

Group type: EXPERIMENTAL
Intervention: Anti-HIV-positive IVDA
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Anti-HIV-positive heterosexual contacts
Number of subjects: 552

Group type: COMPARATOR
Intervention: At-risk groups (both anti-HIV positive and anti-HIV negative)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Subjects with CD4+ lymphocytes < 200/mm3
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Subjects with AIDS-related complex (ARC)/AIDS
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Subjects with stomatitis
Number of subjects: 552
Study: 2529888

Group type: EXPERIMENTAL
Intervention: Lorazepam 50 micrograms kg‐1 by mouth
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hyoscine 6 micrograms kg‐1 i.m.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both groups (lorazepam and hyoscine)
Number of subjects: 33
Study: 30615625

Group type: EXPERIMENTAL
Intervention: #Tamojunto curriculum
Number of subjects: 6391

Group type: COMPARATOR
Intervention: Control condition (no prevention program)
Number of subjects: 6391
Study: 28464006

Group type: EXPERIMENTAL
Intervention: Antenatal education in small classes (3 sessions during pregnancy and 1 after delivery, each lasting 2.5 hours)
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Antenatal education in small classes
Number of subjects: 1766

Group type: COMPARATOR
Intervention: Standard care (2 sessions of 2 hours auditorium-based lectures)
Number of subjects: 1766
Study: 25343945

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 62
Study: 24622318

Group type: EXPERIMENTAL
Intervention: IDeg 3TW(AM)
Number of subjects: 460

Group type: COMPARATOR
Intervention: IGlar OD
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: IDeg 3TW(PM)
Number of subjects: 460
Study: 21551424

Group type: EXPERIMENTAL
Intervention: Commit to Quit video, A Pregnant Woman's Guide to Quit Smoking, and counseling (experimental group)
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Brief routine advice to quit (control group)
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Historical Comparison group (Phase 1)
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Experimental group (Phase 1)
Number of subjects: 1093
Study: 19697647

Group type: EXPERIMENTAL
Intervention: Resilient appliance therapy (T group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonoccluding appliance (C group)
Number of subjects: 48
Study: 16469988

Group type: EXPERIMENTAL
Intervention: Lactoferrin (heat-treated)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lactoferrin (untreated)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lactoferrin (combined)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 20
Study: 15609798

Group type: EXPERIMENTAL
Intervention: Smoking relapse prevention intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cost-effectiveness of smoking cessation
Number of subjects: 0
Study: 10896230

Group type: EXPERIMENTAL
Intervention: rFVIII-FS
Number of subjects: 71
Study: 9492437

Group type: EXPERIMENTAL
Intervention: lipo PGE1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-effective group
Number of subjects: 0
Study: 8318446

Group type: EXPERIMENTAL
Intervention: Sequential constraint during treatment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Quantitative restriction during treatment
Number of subjects: 64
Study: 3566358

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29973195

Group type: EXPERIMENTAL
Intervention: J. regia leaf extract (100 mg, twice daily for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose, twice daily for 8 weeks)
Number of subjects: 40
Study: 28247624

Group type: EXPERIMENTAL
Intervention: Pathogenetic spermatoprotective therapy including zinc and selenium based dietary supplement and chorionic gonadotropin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Etiotropic TB therapy (control group)
Number of subjects: 72
Study: 26002052

Group type: EXPERIMENTAL
Intervention: Riluzole (maximum dose 200 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: D-serine (maximum dose 30 mg/kg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22955689

Group type: EXPERIMENTAL
Intervention: YKL-40 levels in patients with MACE (194±104 μg/L)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: YKL-40 level as a predictor for MACE
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Leukocyte count as a predictor for MACE
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of YKL-40 to predict MACE
Number of subjects: 80
Study: 19919581

Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg i.v., followed by 2 mg/kg/h i.v.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg/kg i.v., followed by 25 mg/kg/h i.v.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline i.v. (control group)
Number of subjects: 120
Study: 17070701

Group type: EXPERIMENTAL
Intervention: Biofeedback + exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 26
Study: 15994216

Group type: EXPERIMENTAL
Intervention: Antiviral treatment with interferon alpha-2b and ribavirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b and ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 14530550

Group type: EXPERIMENTAL
Intervention: Random urine calcium/creatinine ratio (UCa/Cr)
Number of subjects: 324
Study: 10380385

Group type: EXPERIMENTAL
Intervention: Standardized home-care nursing intervention
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no home-care intervention)
Number of subjects: 161
Study: 9055329

Group type: EXPERIMENTAL
Intervention: Dorsal rootlet stimulation during partial dorsal rhizotomy (PDR)
Number of subjects: 6
Study: 1676776

Group type: EXPERIMENTAL
Intervention: Ozone followed by allergen
Number of subjects: 7

Group type: COMPARATOR
Intervention: Air followed by allergen
Number of subjects: 7

Group type: COMPARATOR
Intervention: Air breathing followed by inhalation of allergen diluent (placebo)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ozone followed by inhalation of allergen diluent
Number of subjects: 7
Study: 6634352

Group type: EXPERIMENTAL
Intervention: Olfactory aversion therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Attention placebo control
Number of subjects: 42

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 42
Study: 31589290

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 3154

Group type: EXPERIMENTAL
Intervention: Exendin-4
Number of subjects: 3154

Group type: COMPARATOR
Intervention: GLP-1RA exposure
Number of subjects: 3154
Study: 29433340

Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Worry
Number of subjects: 54

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 54
Study: 27192132

Group type: EXPERIMENTAL
Intervention: 10 minutes of 15.8°C cold water immersion (CWI)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ingestion of 6.8 g/kg‐1 of slushie with application of iced towels to the legs, torso and back/arms (ST)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ingestion of 6.8 g/kg‐1 of room temperature (22.3°C) sports drink (CON)
Number of subjects: 16
Study: 24467770

Group type: EXPERIMENTAL
Intervention: Continuous quality improvement (CQI) intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control condition (initially assigned)
Number of subjects: 8
Study: 22688312

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg loading dose followed by 75 mg maintenance dose
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Ticlopidine 100 mg twice daily
Number of subjects: 1003
Study: 20863927

Group type: EXPERIMENTAL
Intervention: Generic Sevoflurane
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sevorane™
Number of subjects: 64
Study: 18753700

Group type: EXPERIMENTAL
Intervention: Intracoronary bolus tirofiban
Number of subjects: 118
Study: 15842521

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 183
Study: 12684609

Group type: EXPERIMENTAL
Intervention: Amisulpride (400-800 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Risperidone (4-8 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 48

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 48
Study: 10998481

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (12 normal volunteers, 7 men and 5 women, aged 20-45 years)
Number of subjects: 18
Study: 8831181

Group type: EXPERIMENTAL
Intervention: Nifedipine SR 20 mg b.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol (OROS) 14/190 mg o.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of metoprolol and nifedipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1336463

Group type: EXPERIMENTAL
Intervention: lisinopril (20 mg/40 mg o.d.)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: atenolol (50 mg/100 mg o.d.)
Number of subjects: 49

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49
Study: 4016825

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg bolus, intravenous)
Number of subjects: 5
Study: 31060838

Group type: COMPARATOR
Intervention: Standard enteral nutrition (14.1 g/100 mL carbohydrate)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intervention enteral nutrition (7.4 g/100 mL carbohydrate)
Number of subjects: 41
Study: 29706458

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: External radiotherapy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 220
Study: 27081039

Group type: EXPERIMENTAL
Intervention: Prophylactic donor lymphocyte infusion (DLI)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Non-DLI
Number of subjects: 153
Study: 24582316

Group type: EXPERIMENTAL
Intervention: GSK679586 (10 mg/kg, once-monthly intravenous infusions)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: GSK679586
Number of subjects: 198
Study: 22158915

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (PSE) 2.5 mg/kg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (PSE)
Number of subjects: 15
Study: 19880909

Group type: EXPERIMENTAL
Intervention: Inhaled mannitol 420 mg bid for 2 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study: 17972485

Group type: EXPERIMENTAL
Intervention: Upper position with shaded parallelepipeds whose upper/bottom faces were lighter than their side faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upper position with shaded objects whose upper/bottom faces were darker than their side faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower position with shaded parallelepipeds whose upper/bottom faces were lighter than their side faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower position with shaded objects whose upper/bottom faces were darker than their side faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Upper position
Number of subjects: 0
Study: 15723893

Group type: EXPERIMENTAL
Intervention: Cognitive intervention (information and physical exercise)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study: 10831487

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 9332920

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia and single aortic cross‐clamp technique (Group II)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia and conventional partial occluding clamp technique (Group I)
Number of subjects: 100
Study: 8374246

Group type: EXPERIMENTAL
Intervention: Intravenous zinc supplementation for 2 months
Number of subjects: 65
Study: 3946944

Group type: EXPERIMENTAL
Intervention: Ophthalmic timolol (0.5%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 20
Study: 29445852

Group type: EXPERIMENTAL
Intervention: 12-hour patient educational program
Number of subjects: 168

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 168
Study: 26409199

Group type: EXPERIMENTAL
Intervention: Supportive footwear and stretching intervention
Number of subjects: 77
Study: 24136677

Group type: EXPERIMENTAL
Intervention: Minimal access microdiscectomy (MAMD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard open microdiscectomy (SOMD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both MAMD and SOMD
Number of subjects: 60
Study: 21440501

Group type: EXPERIMENTAL
Intervention: AMI patients
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: CABGS patients
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: PCI patients
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 275
Study: 18501861

Group type: EXPERIMENTAL
Intervention: Prenatal drug exposure (PDE) group
Number of subjects: 173

Group type: COMPARATOR
Intervention: Non-drug-exposed children (control group)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Gender comparison (males vs females)
Number of subjects: 173
Study: 16750458

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 864

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 864
Study: 15804071

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/day for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo tablet/day for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal control (healthy adults with BMI < 23 kg/m2)
Number of subjects: 70
Study: 10880268

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regional spinal/epidural anaesthesia
Number of subjects: 12
Study: 9195320

Group type: EXPERIMENTAL
Intervention: Femoral component with a distal centralizing device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Femoral component without a distal centralizing device
Number of subjects: 60
Study: 1555691

Group type: EXPERIMENTAL
Intervention: hMG alone for ovarian stimulation (group A, n = 81)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate and hMG (group B, n = 77)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: 3-day ultrashort course of GnRH-a and hMG (group C, n = 74)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Pituitary desensitization with GnRH-a followed by hMG (group D, n = 76)
Number of subjects: 308

Group type: COMPARATOR
Intervention: All groups (A, B, C, D)
Number of subjects: 308
Study: 3080283

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30324545

Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 56
Study: 27138022

Group type: EXPERIMENTAL
Intervention: Single dose of VGX-1027 (1-800 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple doses of VGX-1027 (40-400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of VGX-1027
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-dose study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug accumulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Excretion of VGX-1027
Number of subjects: 0
Study: 24485998

Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic pyeloplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open pyeloplasty with minimal incision
Number of subjects: 60
Study: 22572058

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention (BAI) offered to trial participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief alcohol intervention (BAI) offered to volunteers
Number of subjects: 0
Study: 20502265

Group type: EXPERIMENTAL
Intervention: Surgical resection of pulmonary metastases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18507669

Group type: EXPERIMENTAL
Intervention: Recurrence quantification analysis (RQA) measures in DM group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Trapping time measure in DM group
Number of subjects: 34
Study: 20216023

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for truncal blocks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional techniques for truncal blocks
Number of subjects: 0
Study: 16360059

Group type: EXPERIMENTAL
Intervention: BDOO pacing
Number of subjects: 19

Group type: COMPARATOR
Intervention: CDOO pacing
Number of subjects: 19

Group type: COMPARATOR
Intervention: AOO pacing
Number of subjects: 19
Study: 12019482

Group type: EXPERIMENTAL
Intervention: Auricularum powder (dexamethasone 10 mg, oxytetracycline HCl 90,000 U, polymyxin B Sulfate 100,000 U, nystatin 1,000,000 U)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin drops (Ciloxan)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tobramycin drops (Tobrex)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All treatments (Auricularum powder, Ciprofloxacin, Tobramycin)
Number of subjects: 120
Study: 9786607

Group type: EXPERIMENTAL
Intervention: Cilnidipine (5 to 20 mg once daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nisoldipine (5 to 20 mg once daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nisoldipine
Number of subjects: 10
Study: 7941918

Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg od
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg bd
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg od
Number of subjects: 230
Study: 2960271

Group type: EXPERIMENTAL
Intervention: Placebo transdermal therapeutic system
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Silver-patch test
Number of subjects: 25
Study: 29145543

Group type: EXPERIMENTAL
Intervention: Ipilimumab, 10 mg/kg, every 21 days for 4 cycles followed by 4 cycles of maintenance therapy every 12 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ipilimumab, 3 mg/kg, every 21 days for 4 cycles (run-in safety cohort)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ipilimumab (overall treatment)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ipilimumab (immune analyses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ipilimumab (immune changes)
Number of subjects: 42
Study: 27871308

Group type: EXPERIMENTAL
Intervention: Telephone information delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 0
Study: 24384905

Group type: EXPERIMENTAL
Intervention: Structured advance care planning (ACP) session by a trained nurse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no structured ACP session)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured ACP session
Number of subjects: 0
Study: 22974314

Group type: EXPERIMENTAL
Intervention: Structured multi-disciplinary team intervention including a gerontology nurse specialist (GNS) intervention, baseline facility needs assessment, quality indicator benchmarking, staff education programme, and care coordination.
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 1700
Study: 21077506

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 3.9 mg transdermal 17beta‐estradiol patch
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 18675097

Group type: EXPERIMENTAL
Intervention: Everolimus (EVL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 40
Study: 16004014

Group type: EXPERIMENTAL
Intervention: Botox injections into one half of the chin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline) injections into the other half of the chin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Botox injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline) injections
Number of subjects: 20
Study: 12857521

Group type: EXPERIMENTAL
Intervention: Shen-Fu (SF) injection (0.5 ml/kg at the beginning of surgery, followed by continuous infusion of 100 ml SF (1.0 ml/kg) diluted in saline at 0.004 ml x Kg(‐1) x min(‐1))
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Shen-Fu (SF) injection
Number of subjects: 38
Study: 10573502

Group type: EXPERIMENTAL
Intervention: Anterolateral paddle position (group AL)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Anteroposterior paddle position (group AP)
Number of subjects: 301
Study: 8948561

Group type: EXPERIMENTAL
Intervention: Daily screening of respiratory function followed by two-hour trials of spontaneous breathing in appropriate patients.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Daily screening without further intervention (control group).
Number of subjects: 300